Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline)
extended-release tablets) in patients with Prader-Willi syndrome.